The BCL2L11 Knockout Jurkat Polyclonal Cells product comprises a polyclonal population of Jurkat cells featuring a targeted disruption of the BCL2L11 gene via CRISPR/Cas9-mediated genome editing. This knockout model is provided as a mixed population of edited cells, enabling researchers to interrogate loss-of-function phenotypes in a genetically heterogeneous pool that captures diverse editing outcomes. The product is designed for applications requiring abrogation of BCL2L11 (BIM) expression in a T lymphoblast background, facilitating studies of apoptosis regulation, signal transduction, and leukemogenesis without the constraints of a single clonal isolate. The CRISPR/Cas9 system was employed to introduce double-strand breaks at the BCL2L11 locus, leading to gene disruption, though the specific editing patterns are not characterized at the clonal level. This polyclonal format maintains biological variability while ensuring robust knockout effects across the population, making it suitable for pooled functional genomics, drug screening, and mechanistic studies.
Jurkat cells are an immortalized human acute T cell leukemia-derived line with a suspension lymphoblast morphology, widely used as a model for T cell signaling, apoptosis, and leukemia biology. Originating from a peripheral blood sample of a 14-year-old patient with relapsed acute lymphoblastic leukemia, these cells harbor constitutive activation of T cell receptor (TCR) signaling pathways and mutations in key tumor suppressors, including PTEN and TP53, making them highly responsive to apoptotic stimuli. The Jurkat background provides a well-characterized platform for dissecting extrinsic and intrinsic apoptotic cascades, cytokine withdrawal responses, and chemotherapeutic drug sensitivity. Their ease of genetic manipulation and consistent growth in suspension culture further enhance their utility for knockout studies, enabling reproducible assessment of gene function in a leukemic context.
BCL2L11 encodes BIM, a pro-apoptotic BH3-only protein that serves as a critical initiator of the intrinsic (mitochondrial) apoptotic pathway. BIM functions by sensing cellular stress signals, including cytokine withdrawal, kinase pathway inhibition, and DNA damage, and then neutralizing anti-apoptotic BCL2 family members such as BCL2, BCL-XL, and MCL-1 while directly or indirectly activating the pore-forming effectors BAX and BAK. Upstream regulators such as FOXO3a, JNK, and ERK signaling converge on BIM to modulate its transcriptional induction, post-translational stabilization, and phosphorylation status, thereby affecting its pro-apoptotic activity. TGF-beta signaling also upregulates BIM in certain contexts. Once activated, BIM integrates these inputs at the mitochondrial surface, where it interacts with the dynein light chain LC8 and engages BAX/BAK to promote mitochondrial outer membrane permeabilization (MOMP). This leads to cytochrome c release, apoptosome formation, and activation of caspase-9 and caspase-3, culminating in cellular demolition. BIM??s interactions with the anti-apoptotic guardians BCL2, BCL-XL, and MCL-1 are central to its function, and its activity is tightly regulated by cytokine-mediated survival signals through the JAK-STAT and MAPK pathways.
In the Jurkat context, disruption of BCL2L11 profoundly impacts T cell apoptosis and leukemic cell homeostasis. Jurkat cells are particularly dependent on BIM for executing apoptosis in response to glucocorticoids, chemotherapeutics, and death receptor ligation, as well as upon IL-2 withdrawal or TCR restimulation. Knockout of BIM in these cells generates a model resistant to intrinsic apoptotic cues, mirroring mechanisms of drug resistance observed in lymphoid malignancies. This polyclonal knockout population is therefore valuable for dissecting BIM??s role in integrating signals from the TCR, JAK-STAT, and MAPK pathways to determine cell fate. It also enables exploration of how BIM deficiency might contribute to autoimmune disease pathogenesis, where defective lymphocyte apoptosis leads to aberrant survival of autoreactive clones. Furthermore, the model facilitates the study of synthetic lethal interactions and the identification of alternative apoptotic pathways that can be therapeutically targeted when BIM function is lost.
Typical applications of BCL2L11 Knockout Jurkat Polyclonal Cells include mechanistic studies of apoptosis signaling, evaluation of drug resistance in leukemia, and screening of BH3 mimetics such as venetoclax that target BCL2-family proteins. Researchers can employ these cells in flow cytometry-based apoptosis assays using Annexin V and TMRE staining to quantify mitochondrial membrane potential loss, or in Western blotting and co-immunoprecipitation experiments to assess BIM interacting partners and downstream caspase activation. RT-qPCR can be used to confirm gene disruption and monitor expression of compensatory regulators. The model also supports cytokine withdrawal-induced apoptosis experiments, where survival signaling through JAK-STAT is abrogated. For further information or to inquire about this product, please contact Ascent Research.
